Zanubrutinib in Waldenström's macroglobulinemia - The phase 3 ASPEN trial

BeiGene

Results from the ASPEN trial (zanubrutinib vs ibrutinib in Waldenström’s macroglobuliemia (WM) patients)

ASPEN is an open-label, randomized, phase 3 study comparing the safety, efficacy and clinical benefit of zanubrutinib with that of ibrutinib in Waldenström’s macroglobuliemia (WM) patients with the MYD88T?7`t mutation. In an additional cohort, the efficacy and safety of zanubrutinib in MYD88 wild type (MYD88Xw) WM patients was evaluated. Zanubrutinib was associated with a CR/VGPR response rate of 28% compared with ibrutinib of 19% (P=0.09). Zanubrutinib demonstrated clinically meaningful advantages in safety and tolerability.

BKQ-J W\` j8n6RHa

gLV0LfL

Please login or register for full access

Register

Already registered?  Login